Form 4: Recursion Pharmaceuticals' Chief Medical Officer Reports Stock Transaction

Sentiment:

SEC Form 4 Filing


David J. Mauro, Chief Medical Officer of Recursion Pharmaceuticals, reports the disposal of 867 shares to cover tax obligations related to restricted stock units.

Summary

  • On May 15, 2024, David J. Mauro, the Chief Medical Officer of Recursion Pharmaceuticals, disposed of 867 shares of Class A Common Stock to satisfy tax withholding obligations.
  • The shares were disposed of at a price of $10.01 per share.
  • Following the transaction, Mauro directly owns 243,762 shares of Class A Common Stock.
  • Mauro also holds options to purchase 99,537 shares at $10.09, vesting monthly from March 1, 2024, and options to purchase 381,426 shares at $8.77, vesting quarterly from June 1, 2024, and then monthly.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a small number of shares being sold by an executive to cover tax obligations.

Key Dates

DateDescription
02/09/2034Expiration date for stock options with an exercise price of $10.09.
06/01/2033Expiration date for stock options with an exercise price of $8.77.
03/01/2024Start date for monthly vesting of stock options with an exercise price of $10.09.
05/15/2024Date of the reported stock transaction.
06/01/2024Start date for quarterly vesting of stock options with an exercise price of $8.77.
05/17/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.